Table 3.
Treatment groups | Body weight (g) |
|||
---|---|---|---|---|
0-time | 2 weeks | 4 weeks | 8 weeks | |
NC | 267.1 ± 11.7 | 314.5 ± 10.2b | 357.9 ± 9.4b | 403.7 ± 10.4b |
DC (STZ) | 261.5 ± 10.4 | 267.6 ± 11.8a | 283.1 ± 12.5a, c | 300.9 ± 11.8a, c |
GLB | 268.6 ± 9.5 | 300.6 ± 13.5 | 320.6 ± 10.2a, b | 353.7 ± 11.2a, b |
MCFE-250 | 269.5 ± 10.8 | 298.7 ± 14.3 | 318.4 ± 9.1a, b | 347.1 ± 13.2a, b |
MCFE-500 | 267.2 ± 12.3 | 303.1 ± 12.5 | 321.8 ± 10.7a, b | 362.9 ± 12.7a, b |
GLB + MCFE-250 | 268.3 ± 11.2 | 304.8 ± 12.7 | 326.1 ± 10.2a, b | 370.4 ± 10.4a, b |
GLB + MCFE-500 | 269.6 ± 9.5 | 312.7 ± 13.3b | 352.5 ± 10.0b, c | 397.2 ± 10.3b, c |
Values are expressed as mean ± SE (n = 6).
Multiple group comparisons were performed by analysis of variance (ANOVA) followed by Tukey’s multiple comparison post hoc test at p ≤ 0.05.
P ≤ 0.05, statistically significant from the normal control (NC) group.
P ≤ 0.05, statistically significant from the diabetic control (DC) group.
P ≤ 0.05, statistically significant from GLB group.